Title of Invention	TRIALZOLE COMPOUNDS
Abstract	A valve for an aerosol comprises a valve body (1) and a surrounding rubber sleeve (2). The body defines an inlet and outlet passages (3, 4) and bores (5, 6) connecting these passages to the surface of the valve. When the pressure of fluid in the inlet passage (3) and bore (5) builds to a sufficient value the sleeve is pushed away from the body permitting flow through the bores between the passages. When the pressure falls the sleeve closes the bores to interrupt the flow.

Title of Invention

TRIALZOLE COMPOUNDS

Abstract

A valve for an aerosol comprises a valve body (1) and a surrounding rubber sleeve (2). The body defines an inlet and outlet passages (3, 4) and bores (5, 6) connecting these passages to the surface of the valve. When the pressure of fluid in the inlet passage (3) and bore (5) builds to a sufficient value the sleeve is pushed away from the body permitting flow through the bores between the passages. When the pressure falls the sleeve closes the bores to interrupt the flow.

Full Text	The present invention relates to triazole compounds and to the use of such compounds. The compounds mentioned have valuable therapeutic properties and can be used for treating diseases which respond to dopamine D3 receptor ligands. Compounds of this type having physiological activity have been disclosed. US-A 4,338,453; 4,408,049 and 4,577,020 describe triazole compounds which have antiallergic or antipsychotic activity. DE-A 44 25 144 and WO 97/25324 describe triazole compounds which respond to dopamine D3 receptor ligands. Compounds of the same structural type, however with other heterocycles in place of the triazole ring are disclosed in DE-A-44 25 146, DE-A-44 25 143 and DE 44 25 145. Neurons obtain their information by way of G protein-coupled receptors, inter alia. A large number of substances exert their effect by way of these receptors. One of these substances is dopamine. It is known with certainty that dopamine is present and that it has a physiological function as a neurotransmitter. Cells responding to dopamine are connected with the etiology of schizophrenia and Parkinson"s disease. These and other diseases are treated with drugs which interact with the dopamine receptors. Prior to 1990, two dopamine receptor subtypes were clearly defined pharmacologically, ie. the Di and D2 receptors. More recently, a third subtype has been found, ie. the D3 receptor, which appears to mediate some of the effects of the antipsychotic drugs. (J.C. Schwartz et al., The Dopamine D3 Receptor as a Target for Antipsychotics, in Novel Antipsychotic Drugs, H.Y. Meltzer, Ed. Raven Press, New York 1992, pages 135-144) D3 receptors are principally expressed in the limbic system. It is therefore assumed that a selective D3 antagonist would probably have the antipsychotic properties of the D2 antagonists but would not have their neurological side effects. (P. Solokoff et al., Localization and Function of the D3 Dopamine Receptor, Arzneim. Forsch./Drug Res. 42(1K 224 (1992); P. Solokoff et al. Molecular Cloning and Characterization of a Novel Dopamine Receptor (D3) as a Target for Neuroleptics, Nature, Ml, 146 (1990)). Surprisingly, it has now been found that certain triazole compounds exhibit a high affinity for the dopamine D3 receptor and a low affinity for the D2 receptor. These compounds are therefore selective D3 ligands. The present invention relates, therefore, to compounds of the formula I: where Ar1 is phenyl, naphthyl or a 5- or 6-membered heterocyclic aromatic ring having from 1, 2, 3 or heteroatoms which are independently selected from 0, S and N, where Ar1 may have 1, 2, 3 or 4 substituents which are selected, independently of each other, from Ci-Cg-alkyl, which may be substituted by OH, OCj-Cg-alkyl, halogen or phenyl, Ci-C6-alkoxy, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, halogen, CN, COOR2, NR2R2, NO2, SO2R2, SC>2NR2R2, or phenyl, which may be substituted by Ci-C6-alkyl, OCi-C6-alkyl, NR2R2, CN, CF3, CHF2, or halogen, and where the heterocyclic, aromatic ring mentioned may be fused to a phenyl ring; A is straight-chain or branched C4-Ci0-alkylene or straight-chain or branched C3-Ci0-alkylene which comprises at least one group Z"which is selected from 0, S, NR2, CONR2, COO, CO, or a double or triple bond, B is a radical of the formula: or, if Ar1 represents the 5- or 6-membered, heterocyclic or aromatic ring which may be substituted as indicated, B may also be a radical of the formulae Ar2 is phenyl, pyridyl, pyrimidinyl or triazinyl, where Ar2 may have from 1 to 4 substituents which are selected, independently of each other, from OR2, C2-C6-alkenyl, Ci-C6 alkyl, C2-C6-alkynyl, Ci-C6-alkoxy-Ci-C6-alkyl, halogen-Ci-C6-alkyl, halogen-Ci-C6-alkoxy, halogen, CN, NO2, S02R2, NR2R2, S02NR2R2, a 5- or 6-membered carbocyclic, aromatic or non-aromatic ring and a 5- or 6-membered, heterocyclic aromatic or non-aromatic ring having from 1 or 2 heteroatoms which are selected from 0, S and N, where the carbocyclic or heterocyclic ring may be substituted by Ci-C6-alkyl, phenyl, phenoxy, halogen, 0Cx-C6-alkyl, OH, N02 or CF3 and where Ar2 may be fused to a carbocyclic or . heterocyclic ring of the above-defined nature, R1 is H, C3-C6-cycloalkyl or Ci-C6-alkyl which may be substituted by OH, 0Ci-C6-alkyl or phenyl; the radicals R2, which can be identical or different, are H or Ci-Ce-alkyl, which may be substituted by OH, OCi-C6-alkyl or phenyl; and their salts with physiologically tolerated acids. The novel compounds are selective dopamine D3 receptor ligands which act in a regioselective manner in a limbic system and which, due to their low affinity for the D2 receptor, have fewer side effects than the classic neuroleptics, which are D2 receptor antagonists. The compounds can therefore be used for treating diseases which respond to dopamine D3 receptor antagonists or dopamine D3 receptor agonists, eg. for treating diseases of the central nervous system, in particular schizophrenia, depressions, neuroses, psychoses, parkinson and anxiety. Within the context of the present invention, the following expressions have the meanings given in conjunction with them: Alkyl (also in radicals such as alkoxy, alkylamino, etc.) is a straight-chain or branched alkyl group having from 1 to 6 carbon atoms and, in particular, from 1 to 4 carbon atoms. The alkyl group can have one or more substituents which are selected, independently of each other, from OH, 0Ci-C6-alkyl, halogen or phenyl. Examples of an alkyl group are methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, etc. Cycloalkyl is, in particular, C3-C6-cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Alkylene radicals are straight-chain or branched. If A does not have any group Z, A then comprises from 4 to 10 carbon atoms, preferably from 4 to 8 carbon atoms. The chain between the triazole nucleus and group B then has at least 4 carbon atoms. If A has at least one of said Z groups, A then comprises from 3 to 10 carbon atoms, preferably from 3 to 8 carbon atoms. If the alkylene groups comprise at least one of the Z groups, these may either be arranged in the alkylene chain at an arbitrary site or in position 1 or 2 of group A (seen from the Ar1 radical). The radicals CONR2 and COO are preferably arranged such that the carbonyl group is facing the triazole ring. Particularly preferred are compounds of the formula I in which A is -Z-C3-C6-alkylene, in particular -Z-CH2CH2CH2-, -Z-CH2CH2CH2CH2-, -Z-CH2CH=CHCH2-, -Z-CH2C(CH3)=CHCH2-, -Z-CH2C(=CH2)CH2-, -Z-CH2CH(CH3)CH2- or a linear -Z-C7-Ci0-alkylene radical, with Z being attached to the triazole ring. Z is preferably CH2, 0 and in particular S. Further preferably is A -(CH2)4-, -(CH2)s-, -CH2CH2CH=CHCH2-, -CH2CH2C(CH3)=CHCH2-, -CH2C(=CH2)CH2-, or -CH2CH2CH(CH3)CH2-. Halogen is F, CI, Br or I. Haloalkyl can comprise one or more, in particular 1, 2, 3 or 4 , halogen atoms which can be located on one or more C atoms, preferably in the a— or co-position. CF3, CHF2, CF2C1 or CH2F are particularly preferred. Acyl is preferably HCO or Ci-Cg-alkyl-CO, in particular acetyl. When Ar1 is substituted, the substituent can also be located on the nitrogen heteroatom. where R3 to R6 are H or the abovementioned substituents of the radical Ar1, R7 is H, Ci-C6-alkyl or phenyl, and X is N or CH. If the phenyl radical is substituted, the substituents are preferably in the m position or the p position. where R3 and R4 have the abovementioned meanings. The phenyl, pyrazinyl and pyrrole radicals which are indicated are particularly preferred. The radicals R3 to R6 are preferably H, Ci-C6-alkyl, OR2, CN, phenyl which may be substituted by Ci-C6-alkyl, Ci-C6-alkoxy or halogen, CF3 and halogen and, in particular, H, Ci-C6-alkyl, OR2 and halogen. In this context, R2 has the abovementioned meanings. The radical B is preferably The radical Ar2 may have one, two, three or four substituents, preferably one or two substituents, which are located, in particular, in the m position and/or the p position. They are preferably selected, independently of each other, from Ci-C6-alkyl, haloalkyl, NO2, halogen, in particular chlorine, phenyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, cyclopentyl and cyclohexyl. When one of the substituents is Cx-C6-alkyl, a branched group and, in particular, isopropyl or t-butyl is preferred. Ar2 is preferably unsubstituted or substituted phenyl, 2-, 3- or 4-pyridinyl or 2-, 4(6)- or 5-pyrimidinyl. When one of the substituents of the radical Ar2 is a 5- or 6-membered heterocyclic ring, the ring is then, for example, a pyrrolidine, piperidine, morpholine, pyridine, pyrimidine, triazine, pyrrole, thiophene, or pyrazole radical, with a pyrrole, pyrrolidine, pyrazole or thienyl radical being preferred. When one of the substituents of the Ar2 radical is a carbocyclic radical, this latter radical is then, in particular, a phenyl, cyclopentyl or cyclohexyl radical. When Ar2 is fused to a carbocyclic radical, this latter radical is, in particular, a naphthalene or dihydro- or tetrahydro-naphthalene radical. According to an embodiment the invention relates to compounds of formula I, wherein Ar1 is a heterocyclic aromatic ring as defined above, B is and A and Ar2 have the meanings given above. The invention also encompasses the acid addition salts of the compounds of the formula I with physiologically tolerated acids. Examples of suitable physiologically tolerated organic and inorganic acids are hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, oxalic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, adipic acid or benzoic acid. Other useful acids are described in Fortschritte der Arzneimittelforschung [Advances in drug research], Volume 10, pages 224 ff., Birkhauser Verlag, Basle and Stuttgart, 1966. The compounds of formula I can have one or more centers of asymmetry. The invention therefore also includes the relevant enantiomers and diastereomers in addition to the racemates. The respective tautomeric forms are also included in the invention. The process for preparing the compound (I) comprises a) reacting a compound of the formula (II) where Y1 is a customary leaving group such as Hal, alkanesulfonyloxy, arylsulfonyloxy, etc., with a compound of the formula (III) HB-Ar2 (HI); or 3) reacting a compound of the formula (IV) where Z1 is 0, NR2, or S and A1 is Ci-Ci0-alkylene or a bond, with a compound of the formula (V) Y1 - A2 - B - Ar2 (V) where Y1 has the abovementioned meaning and A2 is C2-Cio-alkylene, where A1 and A2 together have from 3 to 10 C atoms and A1 and/or A2 optionally comprises at least one group Z; or c) reacting a compound of the formula (VI) (VI) where Y1 and A1 have the abovementioned meanings, with a compound of the formula (VII) H - Zi - A - B - Ar2 (VII) where Z1 has the abovementioned meanings; or d) reversing the polarity of a compound of the formula (VIII) (VIII) using reagents which are known from the literature, such as 1,3-propanedithiol, KCN/water, TMSCN or KCN/morpholine, as described, for example, in Albright Tetrahedron, 1983, 3_9_/ 3207 or D. Seebach Synthesis 1969, 17 and 1979, 19 or H. Stetter Angew. Chem. Int. Ed. 1976, 13., 639 or van Niel et al. Tetrahedron 1989, 4J5, 7643 Martin et al. Synthesis 1979, 633, to give the products (Villa) (using 1,3-propanedithiol by way of example) (Villa) and then chain-elongating with compounds of the formula (IX) Y1 - A3 - B - Ar2 (IX) where Y1 has the abovementioned meanings and A3 is C3-C9-alkylene, which may comprise a group Z to give after deprotecting and reducing, compounds of the formula (la) where Z2 is CO, or a methylene group, and Z2 and A2 together have from 4 to 10 C atoms; or e) reacting a compound of the formula (VIII) with a compound of the formula X Y2 - A - B - Ar2 (X) where Y2 is a phosphorane or a phosphonic acid ester, by a method analogous to customary methods, as described, for example, in Houben Weyl "Handbuch der Organischen Chemie" [Handbook of organic chemistry], 4th edition, Thieme Verlag Stuttgart, Volume 5/lb p. 383 ff. or Volume 5/lc p. 575 ff. The process for preparing a compound of the formula I where A comprises the group COO or CONR2 comprises in reacting a compound of the formula (XI) (XI) where Y3 is OH, OC1-C4, Cl or, together with CO, is an activated carboxyl group, and A4 is C0-C9-alkylene, with a compound of the formula (XII) Z3- A - B - Ar2 (XII) where Z3 is OH or NH2. The compounds of the formula (III) are starting compounds for preparing compounds of the formulae (V), (VII) and (XII), and are prepared by standard methods as described, for example, in J.A. Kiristy et al., J. Med. Chem. 1978, 21, 1303 or C.B. Pollard, J. Am. Chem. Soc. 1934, 56, 2199 or by where Y5 is a boron derivative, such as B(OH)2, or a metal-contaning leaving group, for example SnR3 (R3 = butyl or phenyl) or zinc halide, if Y4 is halogen or trifluoromethyl-sulfonyloxy, or Y5 is halogen or trifluoromethylsulfonyloxy, if Y4 is a boron derivative, such as B(0H)2r or a metal-containing leaving group, for example SnR3 or zinc halide, as described in S. Buchwald et al. Angew. Chem. 1995, 107, 1456 or J.F. Hartwig et al. J.Am. Chem. Soc 1996, 118, 7217 or S. Buchwald J.Org. Chem. 1997, 62, 1264 or F. Kerrigan et al., Tetrah. Lett. 1998, 39, 2219 and the literature cited in that document, or J.K. Stille, Angew. Chem. 1986, 98, 504 or j.K.Stille et al. J.Org.Chem.1990, 55, 3014 or M. Pereyre et al. "Tin in Organic Synthesis", Butterworth 1987; or unsaturated radicals B, using methods which are known from the literature. Compounds of type B are either known or are obtained in a similar way to know methods as e.g. 1,4-diazacycloalkanes: L. Borjeson et al., Acta Chem. Scand. 1991, 45, 621; Majahrzahl et al. Acta. Pol. Pharm., 1975, 32, 145; 1-azacycloheptanones: A. Yokoo et al., Bull Chem. Soc. Jpn. 1956, 29, 631 and WO 97/25324. In the above formulae, Ar1, R1, A, B, Z and Ar2 are as defined above. Compounds of the Ar1-triazole, Ar2" Ar1 type are either known or can be prepared using known methods, as described, for example, in S. Kubota et al. Chem. Pharm. Bull 1975, 23, 955 or A.R. Katritzky, C.W. Rees(ed.) "Comprehensive Heterocyclic Chemistry", Pergamon Press, or "The Chemistry of Heterocyclic Compounds"" J. Wiley&Sons Inc. NY and the literature cited in that document. The compounds of the formula VIII are novel and are likewise part of the subject-matter of the present invention. Compounds of the (VIII) and (XI) type, where A is C0-alkylene, can be prepared by metallating the 3-aryl-5-H-l,2,4(4H)-triazoles and by a method similar to methods described in T. Kauffman et al. Angew. Chem. Int. Ed. Engl. 1972, 11, 846 or by A.R. Katritzky, C.W. Rees(ed.) "Comprehensive Heterocyclic Chemistry", Pergamon Press Vol. 5, p 753. The novel compounds and the starting materials and intermediates can also be prepared by a method similar to the methods described in the patent publications which were cited initially. The above-described reactions generally take place in a solvent at between room temperature and the boiling temperature of the solvent employed. Examples of solvents which can be used are esters, such as ethyl acetate, ethers, such as diethyl ether or tetrahydrofuran, dimethylformamide, dimethyl sulfoxide, dimethoxyethane, toluene, xylene, ketones, such as acetone or methyl ethyl ketone, or alcohols, such as ethanol or butanol. If desired, the reaction can be carried out in the presence of an acid binder. Suitable acid binders are inorganic bases, such as sodium or potassium carbonate, sodium or potassium hydrogen carbonate, sodium ethoxide or sodium hydride, or organometallic compounds, such butyllithium, or alkylmagnesium compounds, or organic bases, such as triethylamine or pyridine. The latter can simultaneously serve as solvents. The reactions may be carried out using a catalyst, such as transition metals and their complexes, eg. Pd(PPh3)4, Pd(OAc)2 or Pd(P(oTol)3)4, or using a phase transfer catalyst, eg. tetrabutylammonium chloride or tetrapropylammonium bromide. The crude product is isolated in a customary manner, for example by filtering, by distilling off the solvent or by extracting from the reaction mixture, etc. The resulting compounds can be purified in a customary manner, for example by recrystallization from a solvent, by chromatography or by conversion into an acid addition compound. The acid addition salts are prepared, in a customary manner, by mixing the free base with the appropriate acid, where appropriate in solution in an organic solvent, for example a lower alcohol, such as methanol, ethanol or propanol, an ether, such as methyl t-butyl ether, a ketone, such as acetone or methyl ethyl ketone, or an ester, such as ethyl acetate. When used for treating the abovementioned diseases, the novel compounds are administered orally or parenterally (subcutaneously, intravenously, intramuscularly, or intraperitoneally) in a customary manner. They can also be administered through the nose/throat region using vapors or sprays. The dose depends on the age, condition and weight of the patient and on the mode of administration. As a rule, the daily dose of active compound is from about 10 to 1000 mg per patient and day in the case of oral administration and from about 1 to 500 mg per patient and day in the case of parenteral administration. The invention also relates to pharmaceuticals which comprise the novel compounds. These pharmaceuticals are present, in the customary pharmacological administration forms, in solid or liquid form, for example as tablets, film tablets, capsules, powders, granules, coated tablets, suppositories, solutions or sprays. In this context, the active compounds can be worked up together with the customary pharmacological auxiliary substances, such as tablet binders, fillers, preservatives, tablet disintegrants, flowance agents, emollients, wetting agents, dispersants, emulsifiers, solubilizers, retarding agents, antioxidants and/or propellant gases (cf. H. Sucker et al., Pharmazeutische Technologie [Pharmaceutical Technology], Thieme-Verlag, Stuttgart, 1978). The resulting administration forms normally comprise the active compound in a quantity of from 1 to 99 % by weight. The following examples serve to explain the invention without limiting it. EXAMPLE 1 3-{3-[4-(2-t-Butyl-6-trifluoromethylpyrimidin-4-yl-)piperazin-l-yl]propylmercapto}-4-methyl-5-phenyl-l,2,4-(4H)-triazole A. Preparation of the starting compounds: A.1 2-t-Butyl-4-[4-(3-chloropropyl)piperazin-1-yl]-6-tri-fluoromethylpyrimidine and 2,2-dimethylpropanimidamide were reacted, in a known manner, with ethyl trifluoroacetate to give 2-(2,2- dimethylethyl)-4-hydroxy-6-trifluoromethylpyrimidine. Heterocyclic Compounds (John Wiley & Sons, 1994, Vol. 52, D.J. Brown (Ed.)). C9H11F3N2O m.p. 187-188° C. A.2 After chlorinating with thionyl chloride, the crude product was treated with an excess of anhydrous piperazine, with 2-t-butyl-4-piperazin-l-yl-6-trifluoromethylpyrimidine being obtained. C13H19F3N4 m p. 78-80° C. A. 3 Alkylating the resulting compound with l-bromo-3-chloropropane in tetrahydrofuran resulted in 2-t-butyl-4-[4-(2-chloropropyl)piperazin-1-yl]-6-trifluoromethylpyrimidine. The inserted triazoles were obtained, if not stated otherwise, according to the method of S. Kubota et al., Chem Pharm Bull. 1975,23,955 by reacting the corresponding acid chlorides with alkyl thio semicarbazides in pyridine followed by cyclization in an aqueous solution of sodium hydrogencarbonate or by addition of the corresponding acid hydrazides with aklkyl thio isocyanates in a suitable solvent. 10.6 g (101.1 mmol) 4-methyl-3-thio semicarbazide and catalytic amounts of dimethyl amino pyridine were added to 10.2 g (45.1 mmol) 2-trichloracetoxy-N-methylpyrrol (obtained according to Rappoport et al., J. Org. Chem. 1972, 37, 3618) in DMF and heated to 90 °C for 18 h. 77 ml of water were added to the resulting product at room temperature, it as acidified with 10 % HC1, stirred for 1 h at 0 °C, filtered from the insoluble, and the original solution was extracted with ethyl acetate. The organic layers were dried, evaporated, and the resulting crude product was heated with a 427 ml solution of 1M sodium hydrogen carbonate to boiling. The original solution was filtered off the insoluble after completion of the reaction, was quenched and acidified with concentrated HCl, and the precipitated solid was isolated. Yield: 2.3 g (27 % of th.) MS: m/z= 194 [M+] 1H-NMR (DMSO-d6): 6 = 3.6 (s,3H); 3.9 (s,3H); 6.2 (m,lH); 6.6 (m,lH); 7.1 (m,lH); 14.0 (1H). B. Preparation of the end product: 576 mg (3 mmol) of 4-mercapto-3-methyl-5-phenyl-l,2,4-(4H)-triazole (prepared in accordance with the method of S. Kubota and M. Uda, Chem. Pharm. Bull. (1975), 23, 955-966 by reacting benzoyl chloride with N-methylthiosemicarbazide and subsequently cyclizing) and 1.1 g (3 mmol) of the chloropropyl compound described above under A.3 were heated, at 100°C for 6 h, together with 7.2 mg (3 mmol) of lithium hydroxide in 10 ml of dry DMF while stirring. After the mixture had cooled down, 50 ml of water were added and the whole was extracted 3 times with t-butyl methyl ether. The organic phase was dried with sodium sulfate and concentrated by evaporation; the residue was purified by column chromatography (silica gel). The resulting pure substance (920 mg = 59 %) was subsequently converted into its hydrochloride using ethereal hydrochloric acid. C25H33CIF3N7S (556) m.p. 191-193°C. The substances of the formula (I) which are listed in the following table were obtained in analogous manner. The compounds of Examples 20-25 and 65 were obtained in the following manner. EXAMPLE 20 3-{3-[4-(2-t-Butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-l-yl]propoxy}-4-methyl-5-phenyl-l,2,4-(4H)-triazole 855 mg (3mmol) of 3-iodo-4-methyl-5-phenyl-l,2,4-(4H)-triazole (prepared by iodinating 4-methyl-5-phenyl-l,2,4-(4H)-triazole by a method similar to Izv. Akad. Nauk SSSR, Ser. Khim (1975), 616-619), were stirred, at 60°C for 6 h, with 1.04 g (3 mmol) of 2-t-butyl-4-[4-(3-hydroxypropyl)piperazin-l-yl]-6-trifluoromethyl pyrimidine (prepared, by a method similar to Example 1, A.3, by reacting the product obtained as described in Example 1, A.2 with 3-chloropropanol) and sodium hydride in DMF. For the working-up, ice water was added to the mixture and the whole was extracted several times with methyl t-butyl ether. The residue which was obtained after drying with sodium sulfate and removing the solvent was purified by column chromatography (silica gel, methylene chloride/methanol). Yield, 140 mg (9 % of theory) of oil C25H32F3N7O (503) 1H NMR (CDCI3): 1.3 (s,9H); 2.1 (m,2H); 2.6-2.8 (m,6H); 3.5 (s,3H); 3.8 (mbr,4H); 4.6 (t,2H); 6.5 (s,lH); 7.6 (m,3H); 7.8 (m,2H); EXAMPLE 21 3-{4-[4-(2,6-Di-t-butylpyrimidin-4-yl)piperazin-l-yl]but-l-enyl}-4-methyl-5-phenyl-l,2,4-(4H)-triazole a. 3-Formyl-4-methyl-5-phenyl-l,2,4-(4H)-triazole 18.5 g (116 mmol) of 4-methyl-5-phenyl-l,2,4-(4H)-triazole were dissolved in 235 ml of absolute THF and the solution was cooled down to -70°C; 85 ml (139 mmol) of a 15% strength solution of butyllithium in hexane were then added at this temperature over the course of 15 min. After 45 min, 72 ml (1.16 mmol) of methyl formate were added over the space of 5 min, in association with which the temperature rose to -50°C. The mixture was subsequently stirred for a further 2 h at -50 to -70°C and for 30 min at -25°C; solid ammonium chloride was then added, after which ice water was added and the whole was extracted 3 times with methylene chloride. After drying and evaporating off the solvent, 22.8 g of residue remained, which residue was purified by means of flash chromatography (silica gel, ethyl acetate/methanol). Yield: 10.9 g (46 % of theory) C10H9N3O (187) 1H NMR (CDCI3) : 3.9 (s,3H); 7.6 (m,3H); 7.7 (m,2H); 10.2 (s,lH). 3-[4-(2,6-Di-t-butylpyrimidin-4-yl)piperazin-1-ylJpropyl-triphenylphosphonium chloride 3.52 g (10 mmol) of l-chloro-3-[4-(2,6-di-t-butylpyrimidin-4-yl)piperazin-l-yl]propane (prepared by a method similar to Example 1, A.3) were dissolved, together with 1.8 g of sodium iodide (12 mmol) and 3.41 g (13 mmol) of triphenylphosphine in 75 ml of acetone and the solution was refluxed for 24 h. After the mixture had been cooled down, the precipitate was filtered off with suction, the filtrate was concentrated by evaporation under reduced pressure and the residue was purified by column chromatography (silica gel, methylene chloride containing 3.5 % methanol). Yield: 6.25 g (88 % of theory). C37H48IN4P (706). 1H NMR (CDCI3): 1.3 (s,9H); 1.4 (s,9H); 1.9 (m,2H); 2.4 (m,4H); 2.7 (m,2H); 3.6 (m,4H); 3.9 (mbr, 2H); 6.3 (s,lH); 7.6-7.9 (m,15H). 5.88 g (8.3 mmol) of the phosphonium salt which was prepared above under b. were dissolved in 15 ml of ethylene glycol dimethyl ether and the solution was cooled down to 0°C; 280 mg (9.2 mmol) of sodium hydride were added and, after the mixture had been stirred at room temperature for 15 min, 1.56 g of the aldehyde described above under a., dissolved in 10 ml of ethylene glycol dimethyl ether, were subsequently added dropwise at 0°C. After the mixture had been stirred at room temperature for 1.5 h and at 40°C for a further 2 h, it was worked up using toluene and water and the insoluble material was removed by filtration. 2.6 g of oil were obtained from the toluene phase after drying and evaporating. Yield: crude product, 65 % of theory. The product was purified by chromatography (silica gel, methylene chloride/methanol). C29H41N7 (487). 1H NMR (CDCI3): 1.3 (s,9H); 1.4 (s,9H); 2.6 (m,8H); 3.7 (m,7H); 6.2 (s,lH); 6.3 (d,lH); 7.0 (td,lH); 7.5 (m,3H); 7.7 (m,2H). EXAMPLE 22 3-{4-[4-(2,6-Di-t-butylpyrimidin-4-yl)piperazin-l-yl]butyl}-4-methyl-5-phenyl-1,2,4-(4H)-triazole a. 2-[4-Methyl-5-phenyl-l,2,4-(4H)-triazol-3-yl]-1,3-dithiane 6.12 g (32.6 mmol) of the aldehyde prepared as described in Example 21 a. were dissolved in 16 ml of chloroform, after which 16 ml of acetic acid, 3.28 ml (32.6 mmol) of 1,3-dimercaptopropane and 160 (xl of boron trifluoride etherate were added at 0°C. After the mixture had been refluxed for 2.5 h, a further 2.4 ml of dimercaptopropane and boron trifluoride etherate were slowly added and the mixture was heated for a further 6 h until the aldehyde had been completely reacted. After the mixture had been cooled down to 0°C, it was adjusted to pH 9-10 with 10% strength sodium hydroxide solution, stirred at 0°C for 1 h and then extracted 3 times with methylene chloride. 13.2 g of a yellow oil were obtained from the dried and evaporated solvent phase and were purified by column chromatography (silica gel, ethyl acetate). Yield: 4.3 g (48 % of theory), colorless solid. C13H15N3S2 (277). 1H NMR (CDCI3): 2.1 (m,2H); 2.9 (m,2H); 3.3 (m,2H); 3.7 (s,3H); 5.3 (s,lH); 7.5 (m,3H); 7.7 (m,2H). b. 831 mg (3 mmol) of the above-described dithiane were dissolved in 7.5 ml of dried THF, and the solution was treated, at -70°C, with 2.2 ml (3.6 mmol) of a 15% strength solution of butyllithium in n-hexane. After the mixture had been stirred at from -70°C to -50°C for 60 min, 1.06 g (3 mmol) of l-chloro-3-[4-(2,6-di-t-butylpyrimidin-4-yl)piperazin-l-yl]propane (prepared by a method similar to Example 1, A.3), dissolved in 5 ml of THF, were added dropwise. The mixture was then warmed slowly to room temperature and heated at 30-50°C for a further 60 min in order to achieve complete reaction. For the working-up, solid ammonium chloride was added to the cooled-down mixture and the latter was then added to ice/water; this mixture was then extracted several times with methylene chloride and methyl-t-butyl ether. Drying and concentrating left a residue of 1.74 g (98 % of theory) of the substituted dithiane, which was subsequently hydrogenated in tetrahydrofuran, at 40°C and over the course of 12 h, using Raney nickel and hydrogen. After the catalyst had been separated off, the residue was purified by chromatography (silica gel, methylene chloride/methanol). Yield: 700 mg (49 % of theory). Colorless solid, m.p. 144-145°C. C29H43N7 (489). EXAMPLE 23 3-{4-[4-(2-t-Butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-1-yl]butyl}-4-methyl-5-phenyl-1,2,4-(4H)-triazole hydrochloride The compound was prepared, by a method similar to Example 22, using the chlorine compound from Example 1, A.3. C29H34F3N7 (502) 1H NMR (CDCI3): 1.3 (s,9H); 1.7 (m,2H); 1.9 (q,2H); 2.4 (t,2H); 2.5 (t,4H); 2.8 (t,2H); 3.6 (s,3H); 3.75 (m,4H); 6.6 (s,lH); 7.4 (m,3H); 7.6 (m,2H). EXAMPLE 24 3_{3_[4_(2-t-Butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-l- yl]propylmercapto}-5-(2,5-dimethylfuran-3-yl)-4-methyltriazole hydrochloride 2,5-Dimethylfuran-3-yl-3-mercapto-4-methyl-l,2,4-(4H)-triazole was obtained by reacting 2,5-dimethylfuran-3-carbonyl chloride with N-methylthiosemicarbazide and subsequently cyclizing in accordance with the method of Kubota and Uda, Chem. Pharm. Bull. (1975), 23, 955-966. C9H11N3OS (209). 1H NMR (CDCI3): 2.2 (s,3H); 2.3 (s,3H); 3.5 (s,3H); 6.5 (1H). The abovementioned compound was obtained by reacting by a method similar to Example IB. M.p. 190-192°C C25H34F3N7OS HC1 (574) EXAMPLE 25 3-{3-[4-2-t-Butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-l-yl]propylmercapto}-5-(pyrazin-2-yl)-4-methyltriazole hydrochloride 3-Mercapto-4-methyl-5-pyrazin-2-yl-l,2,4-(4H)-triazole was obtained by reacting pyrazine-2-carbonyl chloride by a method similar to the method of Kubota and Uda in Example 24. The abovementioned compound was likewise prepared by a method similar to Example IB. M.p. 164-169°C. C23H3iF3N9 (522). Beispiel 65 3-(3-(4-(2-t-Butyl-6-trifluoromethyl-pyrimidin-4-yl)piperazin-1-yl)propylmercapto-4-methyl-5-((1H)-tetrazolyl-5)-1.2 .4(4H)-triazole. a) 3_(3_(4-(2-t-Butyl-6-trifluoromethylpyrimidine-4-yl)piperazin -1-yl)propylmercapto-4-methyl-l.2.4(4H)-triazole-5-carbox-amide 950 mg (6.0 mmol) 5-mercapto-4-methyl-l.2.4(4H)-triazole-3-carboxamide were heated to 100 °C together with 2.2 g (6.0 mmol) of the chlorine base obtained according to example 1.A3 and 144 mg lithiumhydroxide (6.0 mmol) in 17 ml DMF for 3 h while stirring 100 °C. The mixture was then cooled, 100 ml of water were added and the mixture was extracted with methyl-t-butyl ether. Then the solvent layer was dried and evaporated. The residue was purified by chromatography (silica gel, methylene chloride methanol 95:5). Yield: 1.65 g (57 % of th.) mp: 141-143 °C C20H29F3N8OS (MG 486) b) 3-(3-(4-(2-t-Butyl-6-trifluoromethylpyrrimidine-4-yl)pipera- zin-l-yl)propylmercapto-5-cyano-4-methyl-l.2.4(4H)-triazole. 1.15 g (24.0 mmol) of the above described compound were dissolved in 20 ml of methylene chloride and 2 ml (12.0 mmol) of dipropylethylamine, cooled to 0 °C and 0.5 ml trifluoroacetanhydride were slowly added thereto. After stirring for 3 h at room temperature the mixture was washed twice with water, then with a 20 % strength solution of NaHS04, with a saturated solution of NaHC03 and a saline solution; then the organic layer was dried and evaporated. The residue was 0.9 g of an oil (81 % of th.). A sample was transferred into the hydrochloride with etherial hydrogen chloride. mp: 220 - 222 °C C20H27F3N8S (MG 468) C20H2aClF3N8S (MG 503,5) c) 5-(3-(4-(2-t-Butyl-6-trifluoromethylpyrimidine-4-ylJpiperazin -1-yl)propylmercapto-4-methyl-3-((1H)-tetrazolyl-5)- 1.2.4(4H)-triazole. 0.8 g (1.7 mmol) of the above described substance were dissolved in 1 ml of DMF, then 122 mg (1.9 mmol) of sodiumazide and 100 mg (1.9 mmol) of ammonium chloride were added and the mixture was heated to 85 °C for 2 h while stirring. For the working-up a little water was added, the solution was adjusted to ph 7 with NaOH and extracted with methylene chloride. Drying and concentrating left a residue of ca. 1 g which was purified by chromatography (silica gel, methylene chloride methanol 8:2). Yield: 0,38 g (43 % of th.) Fp. 133° (decomposition) C^H.aFaNnS (MG 511) Examples of pharmacological administration forms A) Tablets Tablets of the following composition were molded, in a customary manner, on a compressed-tablet machine: 40 mg of the substance of Example 1 120 mg of corn starch 13.5mg of gelatin 45 mg of lactose 2.25mg of Aerosil® (chemically pure silicic acid which is finely divided to the submicroscopic level) 6.75mg of potato starch (as a 6 % strength paste) B) Coated tablets 20 mg of the substance of Example 4 60 mg of core mass 70 mg of saccharifying mass The core mass consists of 9 parts of corn starch, 3 parts of lactose and 1 part of vinylpyrrolidone/vinyl acetate 60:40 mixed polymer. The saccharifying mass consists of 5 parts of cane sugar, 2 parts of corn starch, 2 parts of calcium carbonate and 1 part of talc. The coated tablets which have been prepared in this way are then provided with a gastric juice-resistant coating. Biological investigations - receptor-binding studies 1) D3-binding test Cloned human D3 receptor-expressing CCL 1,3 mouse fibro¬blasts, which can be obtained from Res. Biochemicals Internat., One Strathmore Rd., Natick, MA 01760-2418 USA, were used for the binding studies. Cell preparation The D3-expessing cells were multiplied in RPMI-1640 containing 10 % fetal calf serum (GIBCO No. 041-32400 N); 100 U/ml penicillin and 0.2 % streptomycin (GIBCO BRL, Gaithersburg, MD, USA). After 48 h, the cells were washed with PBS and incubated for 5 min with 0.05 % trypsin-containing PBS. After that, the mixture was neutralized with medium and the cells were collected by centrifuging at 300 g. In order to lyse the cells, the pellet was briefly washed with lysis buffer (5mM tris-HCl, pH 7.4, containing 10 % glycerol) and then incubated, at 4°C for 30 min, at a concentration of 107 cells/ml of lysis buffer. The cells were centrifuged at 200 g for 10 min and the pellet was stored in liquid nitrogen. Binding tests For the D3 receptor-binding test, the membranes were suspended in incubation buffer (50 mM tris-HCl, pH 7.4, containing 120 mM NaCl, 5 mM KC1, 2 mM CaCl2, 2 mM MgCl2, 10(iM quinolinol, 0.1 % of ascorbic acid and 0.1 % BSA) at a concentration of approx. 106 cells/250 fil of test mixture and incubated at 30°C with 0.1 nM 125iodosulpride in the presence and absence of test substance. The nonspecific binding was determined using 10-6M spiperone. After 60 min, the free and the bound radio ligand were separated by filtration through GF/B glass fiber filters (Whatman, England) on a Skatron cell collector (Skatron, Lier, Norway) and the filters were washed with ice-cold tris-HCl buffer, pH 7.4. The radioactivity which had collected on the filters was quantified using a Packard 2200 CA liquid scintillation counter. The Ki values were determined by means of nonlinear regression analysis using the LIGAND program. 2) D2-binding test Cell culture HEK-293 cells, possessing stably expressed human dopamine D2A receptors, were cultured in RPMI 1640 containing Glutamax I™ and 25 mM HEPES containing 10% fetal calf serum albumin. All E CLAIM: 1. A triazole compound of the formula I where Ar^ Is phenyl, naphthyl or a 5- or B-membered heterocyclic aromatic ring having from 1 to 4 heter-oatoms which are selected, Independently of one another, from 0, S and N, where Ar1 may have 1, 2, 3 or 4 substituents which are selected, independently of each other, from C1-C6-all A is straight-chain or branched C4-C10-alkylene or straight-chain or branched C3-C10-altcylene which comprises at least one Z group which is selected from O, S, NR2, C0NR2, COO, CO, or a double or triple bond, B Is a radical of the formula: or if Ar1 is the 5- or 6-membered heterocyclic aromatic ring which can be substituted as above, B is also a radical of the formulae Ar2 is phenyl, pyridyl, pyrimidinyl or triazinyl, where At^ may have from 1 to 4 substituents which are selected, Independently of each other, from OR^, C1-C6-alkyl, Cj-C6-alkenyl, C2-C6-alkynyi, C^-C6-alkoxy-C1-6-alkyl, halogen-C,-C6-a!kyl, halogen-C1-6-alkoxy, halogen, CN, NOj, SO2R2, NR2R2, SOgNR^R^, a 5- or 6-membered carbocycHc, aromatic or non-aronnatic ring and a 5- or 6-membered, heterocyclic aromatic or non-aromatic ring having 1 or 2 heteroatoms which are selected from O, S and N, where the carbocyclic or heterocyclic ring may be substi¬tuted by C1-6-allcyi, phenyl, phenoxy, halogen, OC1-6-alkyl, OH, NOj or CF3 and/or fused to a phenyl ring and where Ar^ may be. fused to a carbocyclic, aromatic or non-aromatic ring and a 5- or 6-membered, heterocyclic aromatic or non-aromatic ring having 1 or 2 heteroatoms which are selected from O, S and N, R1 is H, Cs-C6-cycioalicyi or C^-C6-ailcyi which may be substituted by OH, OC1-6-allcyl or phenyl, the radicals R2, which can be identical or different, are H or C^-C6-aii^yl, which may be substituted by OH, OC,-C6-alkyl or phenyl; and their salts with physiologically tolerated acids, with the exception of the compounds 2. The compound of the formula I as claimed in claim 1, where Ar^ is phenyl, naphthyl or a 5- or 6-memberecl heteroq/cllc aromatic ring having from 1 to 3 heter-oatoms which are selected from 0, S and N, where Ar1 may have 1,2,3 or 4 substituents which are selected, independently of each other, from C1-6-alkyI, which may be substituted by OH, OC1-6-alkyI, halogen orphenyl, C1-6-alkoxy, C1-6-alkenyl, C2-6-alkynyl, C3-C6-cycloalkyl, halogen, CN, C00R2, NR2R2, NOg, SOgR^. SOgNRSR^ orphenyl, which may be substituted by Ci-C6-all A Is straight-chain or branched C4-C10-alkylene or straight-chain or branched C3-C10-alkylene which comprises at least one group which is selected from O, S, NR2, CONR2, COO, CO, or a double or triple bond, Q is a radical of the famnula: Ar2 is phenyl, pyridyl, pyrimidinyl or triazinyl, where Ar2 may have from 1 to 4 substituents which are selected, independently of each other, from 0R2, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy-C1-C6-alkyl, halogen-C1-6-alkyl, halogen-C1-C6-alkoxy, halogen, CN, NO2, SO2R2, NR2R2, SO2NR2R2, a 5- or 6-membered carbocyclte, aromatic or non-aromatic ring and a 5-or 6-membered, heterocyclic aromatfc or non-aromatic ring having 1 or 2 heteroatoms which are selected from O, S and N, where the carbocydic or heterocyclic ring may be substituted by C1-C6-a)kyl, phenyl, phenoxy, halogen, OC1-C6-alkyI, OH, NO2 or CF3 and where Ar2 may be fused to a carbocydic or heterocyclic ring of the above-defined nature. R^ is H, C3-Ce-cycloalkyl or C1-6-alkyl which may be substituted by OH, OC1-6-alkyl or phenyl; the radicals R2, " which can be identical or different, are H or C1-6-alkyl, which may be substituted by OH, OC1-6-alkyl or phenyl; and their salts with physioiogteatly tolerated acids. 3. The compound of the fonnuia I as claimed In claim 1 or 2, where A Is C4-C10-alkylene or C3-C10-alkylene which may comprise at least one Z group which is selected from O, S and a double or triple bond. \. The compound of the fomnula I as claimed in one of the preceding claims, where Ar^ is phpnyl, naphthyl, pyrrolyl, thienyl, furanyl, thiazolyl, imidazolyl, oxazolyl, oxadlazolyl, tetrazolyl, isoxazolyl, pyridinyi, pyrazinyl, pyrimidinyl, benzthiophenyl, indolyl or benzofuranyl, where Ar^ can, as indicated In claim 1, be substituted or fused. . The compound of the formula I as claimed in claim 4, where Ar^ is phenyl, thienyl, furanyl, tetrazolyl, pyrrolyl or pyrazinyl and can, as indicated in claim 1, be substituted. ). The compound of the formula I as claimed In one of the preceding claims, where Ar^ is unsubstituted or has 1, 2, 3 or 4 substituents whteh are selected. Independently of each other, from CN, C1-6-aikyI, OH, OC1-6-alkyl, phenyl and halogen. 7. The compound of the formula I as claimed In one of the preceding claims, where R1 is H, C1-C6-allcyl or C3-C6- cycloalkyl. 8. The compound of the formula I as claimed In one of the preceding claims, where Ar1 is phenyl, pyridinyl or pyrimidinyl which may have one or two substituents which are selected, independently of each other, from C1-C6-alkyl, C2-C6-alkynyl, halogen, CN, haloall 9. The compound of a formula I as claimed in claim 8, wherein the substituent(s) is/are selected, independently of each other, from C1-C6-alkyI, phenyl, NO2, and halogenoalltyl, in particular CF3, CHF2 and CF2CI. 10. Thecompound of the formula I as claimed In claim 1, where Ar1 is phenyl which may be substituted by C1-C6-alkyl, OC1-C8-alkyl, CN, phenyl or halogen; A has the meanings given in claim 2; B is and Ar2 is pyrimidinyl which may be substituted by C1-6-alkyl, halogen-C1-6-alkyl, halogen-C1-6-aikoxy, pyrrolyl or indolyl. The compound of the formula I as claimed in claim 10, where Ar1 is phenyl which may be substituted by C1-C6-alkyl, OC.,-Ce-alkyl or halogen, and A is -8(CH2)3.10- or -(CH2)4-10-. The compound of the fonnula I as claimed in one of claims 1 to 9, where Ar"" is a 5- or 6-membered heterocyclic aromatic ring having from 1 to 4 heteroatoms which are selected, Independently of each other, from 0. S and N, where the ring can, as indicated in claim 1, be substituted or fused, B is and A and Ai^ have the meanings given in claim 1. ^13. A pharmaceutical composition which comprises at least one compound as claimed in one of claims 1 to 12, with or without physiologically acceptable carrier substance and/or auxiliary substances. 14. A compound of formula VIII where Ar1 and R1 have the meanings given In one of the claims 1, 2, 4 to 7. 10 and 11, with the exception of :ompounds in which R1 is H and Ar1 is phenyl, p-tolyl, 2-, 3-, 4-pyridyl, p-chlorophenyl or p-nltrophenyl.

Full Text

The present invention relates to triazole compounds and to the use of such compounds. The compounds mentioned have valuable therapeutic properties and can be used for treating diseases which respond to dopamine D3 receptor ligands.
Compounds of this type having physiological activity have been disclosed. US-A 4,338,453; 4,408,049 and 4,577,020 describe triazole compounds which have antiallergic or antipsychotic activity. DE-A 44 25 144 and WO 97/25324 describe triazole compounds which respond to dopamine D3 receptor ligands. Compounds of the same structural type, however with other heterocycles in place of the triazole ring are disclosed in DE-A-44 25 146, DE-A-44 25 143 and DE 44 25 145.
Neurons obtain their information by way of G protein-coupled receptors, inter alia. A large number of substances exert their effect by way of these receptors. One of these substances is dopamine.
It is known with certainty that dopamine is present and that it has a physiological function as a neurotransmitter. Cells responding to dopamine are connected with the etiology of schizophrenia and Parkinson"s disease. These and other diseases are treated with drugs which interact with the dopamine receptors.
Prior to 1990, two dopamine receptor subtypes were clearly defined pharmacologically, ie. the Di and D2 receptors.
More recently, a third subtype has been found, ie. the D3 receptor, which appears to mediate some of the effects of the antipsychotic drugs. (J.C. Schwartz et al., The Dopamine D3 Receptor as a Target for Antipsychotics, in Novel Antipsychotic Drugs, H.Y. Meltzer, Ed. Raven Press, New York 1992, pages 135-144)
D3 receptors are principally expressed in the limbic system. It is therefore assumed that a selective D3 antagonist would probably have the antipsychotic properties of the D2 antagonists but would not have their neurological side effects. (P. Solokoff et al., Localization and Function of the D3 Dopamine Receptor, Arzneim. Forsch./Drug Res. 42(1K 224 (1992); P. Solokoff et al. Molecular

Cloning and Characterization of a Novel Dopamine Receptor (D3) as a Target for Neuroleptics, Nature, Ml, 146 (1990)).
Surprisingly, it has now been found that certain triazole compounds exhibit a high affinity for the dopamine D3 receptor and a low affinity for the D2 receptor. These compounds are therefore selective D3 ligands.
The present invention relates, therefore, to compounds of the formula I:
where
Ar1 is phenyl, naphthyl or a 5- or 6-membered heterocyclic
aromatic ring having from 1, 2, 3 or heteroatoms which are independently selected from 0, S and N, where Ar1 may have 1, 2, 3 or 4 substituents which are selected, independently of each other, from Ci-Cg-alkyl, which may be substituted by OH, OCj-Cg-alkyl, halogen or phenyl, Ci-C6-alkoxy, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, halogen, CN, COOR2, NR2R2, NO2, SO2R2, SC>2NR2R2, or phenyl, which may be substituted by Ci-C6-alkyl, OCi-C6-alkyl, NR2R2, CN, CF3, CHF2, or halogen, and where the heterocyclic, aromatic ring mentioned may be fused to a phenyl ring;
A is straight-chain or branched C4-Ci0-alkylene or
straight-chain or branched C3-Ci0-alkylene which comprises at least one group Z"which is selected from 0, S, NR2, CONR2, COO, CO, or a double or triple bond,
B is a radical of the formula:

or, if Ar1 represents the 5- or 6-membered, heterocyclic or aromatic ring which may be substituted as indicated, B may also be a radical of the formulae

Ar2 is phenyl, pyridyl, pyrimidinyl or triazinyl, where Ar2 may have from 1 to 4 substituents which are selected, independently of each other, from OR2, C2-C6-alkenyl, Ci-C6 alkyl, C2-C6-alkynyl, Ci-C6-alkoxy-Ci-C6-alkyl, halogen-Ci-C6-alkyl, halogen-Ci-C6-alkoxy, halogen, CN, NO2, S02R2, NR2R2, S02NR2R2, a 5- or 6-membered carbocyclic, aromatic or non-aromatic ring and a 5- or 6-membered, heterocyclic aromatic or non-aromatic ring having from 1 or 2 heteroatoms which are selected from 0, S and N, where the carbocyclic or heterocyclic ring may be substituted by Ci-C6-alkyl, phenyl, phenoxy, halogen, 0Cx-C6-alkyl, OH, N02 or CF3 and where Ar2 may be fused to a carbocyclic or . heterocyclic ring of the above-defined nature,
R1 is H, C3-C6-cycloalkyl or Ci-C6-alkyl which may be substituted by OH, 0Ci-C6-alkyl or phenyl;
the radicals R2, which can be identical or different, are H or Ci-Ce-alkyl, which may be substituted by OH, OCi-C6-alkyl or phenyl;
and their salts with physiologically tolerated acids.
The novel compounds are selective dopamine D3 receptor ligands which act in a regioselective manner in a limbic system and which, due to their low affinity for the D2 receptor, have fewer side effects than the classic neuroleptics, which are D2 receptor antagonists. The compounds can therefore be used for treating diseases which respond to dopamine D3 receptor antagonists or dopamine D3 receptor agonists, eg. for treating diseases of the central nervous system, in particular schizophrenia, depressions, neuroses, psychoses, parkinson and anxiety.
Within the context of the present invention, the following expressions have the meanings given in conjunction with them:

Alkyl (also in radicals such as alkoxy, alkylamino, etc.) is a straight-chain or branched alkyl group having from 1 to 6 carbon atoms and, in particular, from 1 to 4 carbon atoms. The alkyl group can have one or more substituents which are selected, independently of each other, from OH, 0Ci-C6-alkyl, halogen or phenyl.
Examples of an alkyl group are methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, etc.
Cycloalkyl is, in particular, C3-C6-cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
Alkylene radicals are straight-chain or branched. If A does not have any group Z, A then comprises from 4 to 10 carbon atoms, preferably from 4 to 8 carbon atoms. The chain between the triazole nucleus and group B then has at least 4 carbon atoms. If A has at least one of said Z groups, A then comprises from 3 to 10 carbon atoms, preferably from 3 to 8 carbon atoms.
If the alkylene groups comprise at least one of the Z groups, these may either be arranged in the alkylene chain at an arbitrary site or in position 1 or 2 of group A (seen from the Ar1 radical). The radicals CONR2 and COO are preferably arranged such that the carbonyl group is facing the triazole ring. Particularly preferred are compounds of the formula I in which A is -Z-C3-C6-alkylene, in particular -Z-CH2CH2CH2-, -Z-CH2CH2CH2CH2-, -Z-CH2CH=CHCH2-, -Z-CH2C(CH3)=CHCH2-, -Z-CH2C(=CH2)CH2-, -Z-CH2CH(CH3)CH2- or a linear -Z-C7-Ci0-alkylene radical, with Z being attached to the triazole ring. Z is preferably CH2, 0 and in particular S. Further preferably is A -(CH2)4-, -(CH2)s-, -CH2CH2CH=CHCH2-, -CH2CH2C(CH3)=CHCH2-, -CH2C(=CH2)CH2-, or -CH2CH2CH(CH3)CH2-.
Halogen is F, CI, Br or I.
Haloalkyl can comprise one or more, in particular 1, 2, 3 or 4 , halogen atoms which can be located on one or more C atoms, preferably in the a— or co-position. CF3, CHF2, CF2C1 or CH2F are particularly preferred.
Acyl is preferably HCO or Ci-Cg-alkyl-CO, in particular acetyl. When Ar1 is substituted, the substituent can also be located on the nitrogen heteroatom.

where
R3 to R6 are H or the abovementioned substituents of the radical
Ar1,
R7 is H, Ci-C6-alkyl or phenyl, and
X is N or CH. If the phenyl radical is substituted, the substituents are preferably in the m position or the p position.

where R3 and R4 have the abovementioned meanings. The phenyl, pyrazinyl and pyrrole radicals which are indicated are particularly preferred.
The radicals R3 to R6 are preferably H, Ci-C6-alkyl, OR2, CN, phenyl which may be substituted by Ci-C6-alkyl, Ci-C6-alkoxy or halogen, CF3 and halogen and, in particular, H, Ci-C6-alkyl, OR2 and halogen. In this context, R2 has the abovementioned meanings.
The radical B is preferably

The radical Ar2 may have one, two, three or four substituents, preferably one or two substituents, which are located, in particular, in the m position and/or the p position. They are preferably selected, independently of each other, from Ci-C6-alkyl, haloalkyl, NO2, halogen, in particular chlorine, phenyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, cyclopentyl and cyclohexyl. When one of the substituents is Cx-C6-alkyl, a branched group and, in particular, isopropyl or t-butyl is preferred.
Ar2 is preferably unsubstituted or substituted phenyl, 2-, 3- or 4-pyridinyl or 2-, 4(6)- or 5-pyrimidinyl.
When one of the substituents of the radical Ar2 is a 5- or 6-membered heterocyclic ring, the ring is then, for example, a pyrrolidine, piperidine, morpholine, pyridine, pyrimidine, triazine, pyrrole, thiophene, or pyrazole radical, with a pyrrole, pyrrolidine, pyrazole or thienyl radical being preferred.
When one of the substituents of the Ar2 radical is a carbocyclic radical, this latter radical is then, in particular, a phenyl, cyclopentyl or cyclohexyl radical.

When Ar2 is fused to a carbocyclic radical, this latter radical is, in particular, a naphthalene or dihydro- or tetrahydro-naphthalene radical.
According to an embodiment the invention relates to compounds of formula I, wherein Ar1 is a heterocyclic aromatic ring as defined above, B is

and A and Ar2 have the meanings given above.
The invention also encompasses the acid addition salts of the compounds of the formula I with physiologically tolerated acids. Examples of suitable physiologically tolerated organic and inorganic acids are hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, oxalic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, adipic acid or benzoic acid. Other useful acids are described in Fortschritte der Arzneimittelforschung [Advances in drug research], Volume 10, pages 224 ff., Birkhauser Verlag, Basle and Stuttgart, 1966.
The compounds of formula I can have one or more centers of asymmetry. The invention therefore also includes the relevant enantiomers and diastereomers in addition to the racemates. The respective tautomeric forms are also included in the invention.
The process for preparing the compound (I) comprises
a) reacting a compound of the formula (II)

where Y1 is a customary leaving group such as Hal, alkanesulfonyloxy, arylsulfonyloxy, etc., with a compound of the formula (III)
HB-Ar2 (HI);
or
3) reacting a compound of the formula (IV)

where Z1 is 0, NR2, or S and A1 is Ci-Ci0-alkylene or a bond, with a compound of the formula (V)
Y1 - A2 - B - Ar2 (V)
where Y1 has the abovementioned meaning and A2 is C2-Cio-alkylene, where A1 and A2 together have from 3 to 10 C atoms and A1 and/or A2 optionally comprises at least one group Z; or

c) reacting a compound of the formula (VI)
(VI)
where Y1 and A1 have the abovementioned meanings, with a compound of the formula (VII)
H - Zi - A - B - Ar2 (VII)
where Z1 has the abovementioned meanings; or
d) reversing the polarity of a compound of the formula (VIII)
(VIII)
using reagents which are known from the literature, such as 1,3-propanedithiol, KCN/water, TMSCN or KCN/morpholine, as described, for example, in
Albright Tetrahedron, 1983, 3_9_/ 3207 or
D. Seebach Synthesis 1969, 17 and 1979, 19 or
H. Stetter Angew. Chem. Int. Ed. 1976, 13., 639 or
van Niel et al. Tetrahedron 1989, 4J5, 7643
Martin et al. Synthesis 1979, 633,
to give the products (Villa) (using 1,3-propanedithiol by way of example)
(Villa) and then chain-elongating with compounds of the formula (IX)

Y1 - A3 - B - Ar2 (IX)
where Y1 has the abovementioned meanings and A3 is C3-C9-alkylene, which may comprise a group Z
to give after deprotecting and reducing, compounds of the formula (la)

where Z2 is CO, or a methylene group, and Z2 and A2 together have from 4 to 10 C atoms;
or
e) reacting a compound of the formula (VIII) with a compound of the formula X
Y2 - A - B - Ar2 (X)
where Y2 is a phosphorane or a phosphonic acid ester, by a method analogous to customary methods, as described, for example, in Houben Weyl "Handbuch der Organischen Chemie" [Handbook of organic chemistry], 4th edition, Thieme Verlag Stuttgart, Volume 5/lb p. 383 ff. or Volume 5/lc p. 575 ff.
The process for preparing a compound of the formula I where A comprises the group COO or CONR2 comprises in reacting a compound of the formula (XI)
(XI)
where Y3 is OH, OC1-C4, Cl or, together with CO, is an activated carboxyl group, and A4 is C0-C9-alkylene, with a compound of the formula (XII)
Z3- A - B - Ar2 (XII)

where Z3 is OH or NH2.
The compounds of the formula (III) are starting compounds for preparing compounds of the formulae (V), (VII) and (XII), and are prepared by standard methods as described, for example, in J.A. Kiristy et al., J. Med. Chem. 1978, 21, 1303 or C.B. Pollard, J. Am. Chem. Soc. 1934, 56, 2199 or by

where Y5 is a boron derivative, such as B(OH)2, or a metal-contaning leaving group, for example SnR3 (R3 = butyl or phenyl) or zinc halide, if Y4 is halogen or trifluoromethyl-sulfonyloxy, or Y5 is halogen or trifluoromethylsulfonyloxy, if Y4 is a boron derivative, such as B(0H)2r or a metal-containing leaving group, for example SnR3 or zinc halide, as described in
S. Buchwald et al. Angew. Chem. 1995, 107, 1456 or J.F. Hartwig et al. J.Am. Chem. Soc 1996, 118, 7217 or
S. Buchwald J.Org. Chem. 1997, 62, 1264 or F. Kerrigan et al., Tetrah. Lett. 1998, 39, 2219 and the literature cited in that document, or
J.K. Stille, Angew. Chem. 1986, 98, 504 or
j.K.Stille et al. J.Org.Chem.1990, 55, 3014 or
M. Pereyre et al. "Tin in Organic Synthesis", Butterworth 1987; or

unsaturated radicals B, using methods which are known from the literature.
Compounds of type B are either known or are obtained in a similar way to know methods as e.g. 1,4-diazacycloalkanes: L. Borjeson et al., Acta Chem. Scand. 1991, 45, 621; Majahrzahl et al. Acta. Pol. Pharm., 1975, 32, 145; 1-azacycloheptanones: A. Yokoo et al., Bull Chem. Soc. Jpn. 1956, 29, 631 and WO 97/25324.
In the above formulae, Ar1, R1, A, B, Z and Ar2 are as defined above.
Compounds of the Ar1-triazole, Ar2" Ar1 type are either known or can be prepared using known methods, as described, for example, in S. Kubota et al. Chem. Pharm. Bull 1975, 23, 955 or A.R. Katritzky, C.W. Rees(ed.) "Comprehensive Heterocyclic Chemistry", Pergamon Press, or "The Chemistry of Heterocyclic Compounds"" J. Wiley&Sons Inc. NY and the literature cited in that document.
The compounds of the formula VIII are novel and are likewise part of the subject-matter of the present invention.
Compounds of the (VIII) and (XI) type, where A is C0-alkylene, can be prepared by metallating the 3-aryl-5-H-l,2,4(4H)-triazoles

and by a method similar to methods described in T. Kauffman et al. Angew. Chem. Int. Ed. Engl. 1972, 11, 846 or by A.R. Katritzky, C.W. Rees(ed.) "Comprehensive Heterocyclic Chemistry", Pergamon Press Vol. 5, p 753.
The novel compounds and the starting materials and intermediates can also be prepared by a method similar to the methods described in the patent publications which were cited initially.
The above-described reactions generally take place in a solvent at between room temperature and the boiling temperature of the solvent employed. Examples of solvents which can be used are esters, such as ethyl acetate, ethers, such as diethyl ether or tetrahydrofuran, dimethylformamide, dimethyl sulfoxide,

dimethoxyethane, toluene, xylene, ketones, such as acetone or methyl ethyl ketone, or alcohols, such as ethanol or butanol.
If desired, the reaction can be carried out in the presence of an acid binder. Suitable acid binders are inorganic bases, such as sodium or potassium carbonate, sodium or potassium hydrogen carbonate, sodium ethoxide or sodium hydride, or organometallic compounds, such butyllithium, or alkylmagnesium compounds, or organic bases, such as triethylamine or pyridine. The latter can simultaneously serve as solvents.
The reactions may be carried out using a catalyst, such as transition metals and their complexes, eg. Pd(PPh3)4, Pd(OAc)2 or Pd(P(oTol)3)4, or using a phase transfer catalyst, eg. tetrabutylammonium chloride or tetrapropylammonium bromide.
The crude product is isolated in a customary manner, for example by filtering, by distilling off the solvent or by extracting from the reaction mixture, etc. The resulting compounds can be purified in a customary manner, for example by recrystallization from a solvent, by chromatography or by conversion into an acid addition compound.
The acid addition salts are prepared, in a customary manner, by mixing the free base with the appropriate acid, where appropriate in solution in an organic solvent, for example a lower alcohol, such as methanol, ethanol or propanol, an ether, such as methyl t-butyl ether, a ketone, such as acetone or methyl ethyl ketone, or an ester, such as ethyl acetate.
When used for treating the abovementioned diseases, the novel compounds are administered orally or parenterally (subcutaneously, intravenously, intramuscularly, or intraperitoneally) in a customary manner. They can also be administered through the nose/throat region using vapors or sprays.
The dose depends on the age, condition and weight of the patient and on the mode of administration. As a rule, the daily dose of active compound is from about 10 to 1000 mg per patient and day in the case of oral administration and from about 1 to 500 mg per patient and day in the case of parenteral administration.

The invention also relates to pharmaceuticals which comprise the novel compounds. These pharmaceuticals are present, in the customary pharmacological administration forms, in solid or liquid form, for example as tablets, film tablets, capsules, powders, granules, coated tablets, suppositories, solutions or sprays. In this context, the active compounds can be worked up together with the customary pharmacological auxiliary substances, such as tablet binders, fillers, preservatives, tablet disintegrants, flowance agents, emollients, wetting agents, dispersants, emulsifiers, solubilizers, retarding agents, antioxidants and/or propellant gases (cf. H. Sucker et al., Pharmazeutische Technologie [Pharmaceutical Technology], Thieme-Verlag, Stuttgart, 1978). The resulting administration forms normally comprise the active compound in a quantity of from 1 to 99 % by weight.
The following examples serve to explain the invention without limiting it.
EXAMPLE 1
3-{3-[4-(2-t-Butyl-6-trifluoromethylpyrimidin-4-yl-)piperazin-l-yl]propylmercapto}-4-methyl-5-phenyl-l,2,4-(4H)-triazole
A. Preparation of the starting compounds:
A.1 2-t-Butyl-4-[4-(3-chloropropyl)piperazin-1-yl]-6-tri-fluoromethylpyrimidine and 2,2-dimethylpropanimidamide were reacted, in a known manner, with ethyl trifluoroacetate to give 2-(2,2-
dimethylethyl)-4-hydroxy-6-trifluoromethylpyrimidine. Heterocyclic Compounds (John Wiley & Sons, 1994, Vol. 52, D.J. Brown (Ed.)).
C9H11F3N2O m.p. 187-188° C.
A.2 After chlorinating with thionyl chloride, the crude product was treated with an excess of anhydrous piperazine, with 2-t-butyl-4-piperazin-l-yl-6-trifluoromethylpyrimidine being obtained.
C13H19F3N4 m p. 78-80° C.

A. 3 Alkylating the resulting compound with
l-bromo-3-chloropropane in tetrahydrofuran resulted in 2-t-butyl-4-[4-(2-chloropropyl)piperazin-1-yl]-6-trifluoromethylpyrimidine.

The inserted triazoles were obtained, if not stated otherwise, according to the method of S. Kubota et al., Chem Pharm Bull. 1975,23,955 by reacting the corresponding acid chlorides with alkyl thio semicarbazides in pyridine followed by cyclization in an aqueous solution of sodium hydrogencarbonate or by addition of the corresponding acid hydrazides with aklkyl thio isocyanates in a suitable solvent.

10.6 g (101.1 mmol) 4-methyl-3-thio semicarbazide and catalytic amounts of dimethyl amino pyridine were added to 10.2 g (45.1 mmol) 2-trichloracetoxy-N-methylpyrrol (obtained according to Rappoport et al., J. Org. Chem. 1972, 37, 3618) in DMF and heated to 90 °C for 18 h. 77 ml of water were added to the resulting product at room temperature, it as acidified with 10 % HC1, stirred for 1 h at 0 °C, filtered from the insoluble, and the original solution was extracted with ethyl acetate. The organic layers were dried, evaporated, and the resulting crude product was heated with a 427 ml solution of 1M sodium hydrogen carbonate to boiling. The original solution was filtered off the insoluble after completion of the reaction, was quenched and acidified with concentrated HCl, and the precipitated solid was isolated. Yield: 2.3 g (27 % of th.) MS: m/z= 194 [M+]
1H-NMR (DMSO-d6): 6 = 3.6 (s,3H); 3.9 (s,3H); 6.2 (m,lH); 6.6 (m,lH); 7.1 (m,lH); 14.0 (1H).
B. Preparation of the end product:
576 mg (3 mmol) of 4-mercapto-3-methyl-5-phenyl-l,2,4-(4H)-triazole (prepared in accordance with the method of S. Kubota and M. Uda, Chem. Pharm. Bull. (1975), 23, 955-966 by reacting benzoyl chloride with N-methylthiosemicarbazide and subsequently cyclizing) and 1.1 g (3 mmol) of the chloropropyl compound described above under A.3 were heated, at 100°C for 6 h, together with 7.2 mg (3 mmol) of lithium

hydroxide in 10 ml of dry DMF while stirring. After the mixture had cooled down, 50 ml of water were added and the whole was extracted 3 times with t-butyl methyl ether. The organic phase was dried with sodium sulfate and concentrated by evaporation; the residue was purified by column chromatography (silica gel). The resulting pure substance (920 mg = 59 %) was subsequently converted into its hydrochloride using ethereal hydrochloric acid.
C25H33CIF3N7S (556) m.p. 191-193°C.
The substances of the formula (I) which are listed in the following table were obtained in analogous manner.

The compounds of Examples 20-25 and 65 were obtained in the following manner.
EXAMPLE 20
3-{3-[4-(2-t-Butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-l-yl]propoxy}-4-methyl-5-phenyl-l,2,4-(4H)-triazole
855 mg (3mmol) of 3-iodo-4-methyl-5-phenyl-l,2,4-(4H)-triazole (prepared by iodinating 4-methyl-5-phenyl-l,2,4-(4H)-triazole by a method similar to Izv. Akad. Nauk SSSR, Ser. Khim (1975), 616-619), were stirred, at 60°C for 6 h, with 1.04 g (3 mmol) of 2-t-butyl-4-[4-(3-hydroxypropyl)piperazin-l-yl]-6-trifluoromethyl pyrimidine (prepared, by a method similar to Example 1, A.3, by reacting the product obtained as described in Example 1, A.2 with 3-chloropropanol) and sodium hydride in DMF. For the working-up, ice water was added to the mixture and the whole was extracted several times with methyl t-butyl ether. The residue which was obtained after drying with sodium sulfate and removing the solvent was purified by column chromatography (silica gel, methylene chloride/methanol). Yield, 140 mg (9 % of theory) of oil
C25H32F3N7O (503)
1H NMR (CDCI3):
1.3 (s,9H); 2.1 (m,2H); 2.6-2.8 (m,6H); 3.5 (s,3H); 3.8 (mbr,4H); 4.6 (t,2H); 6.5 (s,lH); 7.6 (m,3H); 7.8 (m,2H);
EXAMPLE 21
3-{4-[4-(2,6-Di-t-butylpyrimidin-4-yl)piperazin-l-yl]but-l-enyl}-4-methyl-5-phenyl-l,2,4-(4H)-triazole
a. 3-Formyl-4-methyl-5-phenyl-l,2,4-(4H)-triazole
18.5 g (116 mmol) of 4-methyl-5-phenyl-l,2,4-(4H)-triazole were dissolved in 235 ml of absolute THF and the solution was cooled down to -70°C; 85 ml (139 mmol) of a 15% strength solution of butyllithium in hexane were then added at this temperature over the course of 15 min. After 45 min, 72 ml (1.16 mmol) of methyl formate were added over the space of 5 min, in association with which the temperature rose to -50°C. The mixture was subsequently stirred for a further 2 h

at -50 to -70°C and for 30 min at -25°C; solid ammonium chloride was then added, after which ice water was added and the whole was extracted 3 times with methylene chloride. After drying and evaporating off the solvent, 22.8 g of residue remained, which residue was purified by means of flash chromatography (silica gel, ethyl acetate/methanol). Yield: 10.9 g (46 % of theory)
C10H9N3O (187)
1H NMR (CDCI3) :
3.9 (s,3H); 7.6 (m,3H); 7.7 (m,2H); 10.2 (s,lH).
3-[4-(2,6-Di-t-butylpyrimidin-4-yl)piperazin-1-ylJpropyl-triphenylphosphonium chloride
3.52 g (10 mmol) of l-chloro-3-[4-(2,6-di-t-butylpyrimidin-4-yl)piperazin-l-yl]propane (prepared by a method similar to Example 1, A.3) were dissolved, together with 1.8 g of sodium iodide (12 mmol) and 3.41 g (13 mmol) of triphenylphosphine in 75 ml of acetone and the solution was refluxed for 24 h.
After the mixture had been cooled down, the precipitate was filtered off with suction, the filtrate was concentrated by evaporation under reduced pressure and the residue was purified by column chromatography (silica gel, methylene chloride containing 3.5 % methanol). Yield: 6.25 g (88 % of theory).
C37H48IN4P (706).
1H NMR (CDCI3):
1.3 (s,9H); 1.4 (s,9H); 1.9 (m,2H); 2.4 (m,4H); 2.7 (m,2H);
3.6 (m,4H); 3.9 (mbr, 2H); 6.3 (s,lH); 7.6-7.9 (m,15H).
5.88 g (8.3 mmol) of the phosphonium salt which was prepared above under b. were dissolved in 15 ml of ethylene glycol dimethyl ether and the solution was cooled down to 0°C; 280 mg (9.2 mmol) of sodium hydride were added and, after the mixture had been stirred at room temperature for 15 min, 1.56 g of the aldehyde described above under a., dissolved in 10 ml of ethylene glycol dimethyl ether, were subsequently added dropwise at 0°C.
After the mixture had been stirred at room temperature for 1.5 h and at 40°C for a further 2 h, it was worked up using toluene and water and the insoluble material was removed by

filtration. 2.6 g of oil were obtained from the toluene phase after drying and evaporating. Yield: crude product, 65 % of theory.
The product was purified by chromatography (silica gel, methylene chloride/methanol).
C29H41N7 (487).
1H NMR (CDCI3):
1.3 (s,9H); 1.4 (s,9H); 2.6 (m,8H); 3.7 (m,7H); 6.2 (s,lH);
6.3 (d,lH); 7.0 (td,lH); 7.5 (m,3H); 7.7 (m,2H).
EXAMPLE 22
3-{4-[4-(2,6-Di-t-butylpyrimidin-4-yl)piperazin-l-yl]butyl}-4-methyl-5-phenyl-1,2,4-(4H)-triazole
a. 2-[4-Methyl-5-phenyl-l,2,4-(4H)-triazol-3-yl]-1,3-dithiane
6.12 g (32.6 mmol) of the aldehyde prepared as described in Example 21 a. were dissolved in 16 ml of chloroform, after which 16 ml of acetic acid, 3.28 ml (32.6 mmol) of 1,3-dimercaptopropane and 160 (xl of boron trifluoride etherate were added at 0°C. After the mixture had been refluxed for 2.5 h, a further 2.4 ml of dimercaptopropane and boron trifluoride etherate were slowly added and the mixture was heated for a further 6 h until the aldehyde had been completely reacted.
After the mixture had been cooled down to 0°C, it was adjusted to pH 9-10 with 10% strength sodium hydroxide solution, stirred at 0°C for 1 h and then extracted 3 times with methylene chloride. 13.2 g of a yellow oil were obtained from the dried and evaporated solvent phase and were purified by column chromatography (silica gel, ethyl acetate). Yield: 4.3 g (48 % of theory), colorless solid. C13H15N3S2 (277).
1H NMR (CDCI3):
2.1 (m,2H); 2.9 (m,2H); 3.3 (m,2H); 3.7 (s,3H); 5.3 (s,lH);
7.5 (m,3H); 7.7 (m,2H).
b. 831 mg (3 mmol) of the above-described dithiane were
dissolved in 7.5 ml of dried THF, and the solution was
treated, at -70°C, with 2.2 ml (3.6 mmol) of a 15% strength

solution of butyllithium in n-hexane. After the mixture had been stirred at from -70°C to -50°C for 60 min, 1.06 g (3 mmol) of l-chloro-3-[4-(2,6-di-t-butylpyrimidin-4-yl)piperazin-l-yl]propane (prepared by a method similar to Example 1, A.3), dissolved in 5 ml of THF, were added dropwise. The mixture was then warmed slowly to room temperature and heated at 30-50°C for a further 60 min in order to achieve complete reaction. For the working-up, solid ammonium chloride was added to the cooled-down mixture and the latter was then added to ice/water; this mixture was then extracted several times with methylene chloride and methyl-t-butyl ether. Drying and concentrating left a residue of 1.74 g (98 % of theory) of the substituted dithiane, which was subsequently hydrogenated in tetrahydrofuran, at 40°C and over the course of 12 h, using Raney nickel and hydrogen. After the catalyst had been separated off, the residue was purified by chromatography (silica gel, methylene chloride/methanol). Yield: 700 mg (49 % of theory). Colorless solid, m.p. 144-145°C. C29H43N7 (489).
EXAMPLE 23
3-{4-[4-(2-t-Butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-1-yl]butyl}-4-methyl-5-phenyl-1,2,4-(4H)-triazole hydrochloride
The compound was prepared, by a method similar to Example 22, using the chlorine compound from Example 1, A.3.
C29H34F3N7 (502)
1H NMR (CDCI3):
1.3 (s,9H); 1.7 (m,2H); 1.9 (q,2H); 2.4 (t,2H); 2.5 (t,4H); 2.8 (t,2H); 3.6 (s,3H); 3.75 (m,4H); 6.6 (s,lH); 7.4 (m,3H); 7.6 (m,2H).
EXAMPLE 24
3_{3_[4_(2-t-Butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-l-
yl]propylmercapto}-5-(2,5-dimethylfuran-3-yl)-4-methyltriazole
hydrochloride

2,5-Dimethylfuran-3-yl-3-mercapto-4-methyl-l,2,4-(4H)-triazole was obtained by reacting 2,5-dimethylfuran-3-carbonyl chloride with N-methylthiosemicarbazide and subsequently cyclizing in accordance with the method of Kubota and Uda, Chem. Pharm. Bull. (1975), 23, 955-966.
C9H11N3OS (209).
1H NMR (CDCI3):
2.2 (s,3H); 2.3 (s,3H); 3.5 (s,3H); 6.5 (1H).
The abovementioned compound was obtained by reacting by a method similar to Example IB. M.p. 190-192°C
C25H34F3N7OS HC1 (574)
EXAMPLE 25
3-{3-[4-2-t-Butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-l-yl]propylmercapto}-5-(pyrazin-2-yl)-4-methyltriazole hydrochloride
3-Mercapto-4-methyl-5-pyrazin-2-yl-l,2,4-(4H)-triazole was obtained by reacting pyrazine-2-carbonyl chloride by a method similar to the method of Kubota and Uda in Example 24.
The abovementioned compound was likewise prepared by a method similar to Example IB. M.p. 164-169°C.
C23H3iF3N9 (522).
Beispiel 65
3-(3-(4-(2-t-Butyl-6-trifluoromethyl-pyrimidin-4-yl)piperazin-1-yl)propylmercapto-4-methyl-5-((1H)-tetrazolyl-5)-1.2 .4(4H)-triazole.
a) 3_(3_(4-(2-t-Butyl-6-trifluoromethylpyrimidine-4-yl)piperazin -1-yl)propylmercapto-4-methyl-l.2.4(4H)-triazole-5-carbox-amide
950 mg (6.0 mmol) 5-mercapto-4-methyl-l.2.4(4H)-triazole-3-carboxamide were heated to 100 °C together with 2.2 g (6.0 mmol) of the chlorine base obtained according to example 1.A3 and 144 mg lithiumhydroxide (6.0 mmol) in 17 ml DMF for 3 h while stirring 100 °C. The mixture was then cooled, 100 ml of water were added and the mixture was extracted with

methyl-t-butyl ether. Then the solvent layer was dried and evaporated. The residue was purified by chromatography (silica gel, methylene chloride methanol 95:5).
Yield: 1.65 g (57 % of th.) mp: 141-143 °C C20H29F3N8OS (MG 486)
b) 3-(3-(4-(2-t-Butyl-6-trifluoromethylpyrrimidine-4-yl)pipera-
zin-l-yl)propylmercapto-5-cyano-4-methyl-l.2.4(4H)-triazole.
1.15 g (24.0 mmol) of the above described compound were dissolved in 20 ml of methylene chloride and 2 ml (12.0 mmol) of dipropylethylamine, cooled to 0 °C and 0.5 ml trifluoroacetanhydride were slowly added thereto. After stirring for 3 h at room temperature the mixture was washed twice with water, then with a 20 % strength solution of NaHS04, with a saturated solution of NaHC03 and a saline solution; then the organic layer was dried and evaporated. The residue was 0.9 g of an oil (81 % of th.). A sample was transferred into the hydrochloride with etherial hydrogen chloride.
mp: 220 - 222 °C C20H27F3N8S (MG 468) C20H2aClF3N8S (MG 503,5)
c) 5-(3-(4-(2-t-Butyl-6-trifluoromethylpyrimidine-4-ylJpiperazin
-1-yl)propylmercapto-4-methyl-3-((1H)-tetrazolyl-5)-
1.2.4(4H)-triazole.
0.8 g (1.7 mmol) of the above described substance were dissolved in 1 ml of DMF, then 122 mg (1.9 mmol) of sodiumazide and 100 mg (1.9 mmol) of ammonium chloride were added and the mixture was heated to 85 °C for 2 h while stirring. For the working-up a little water was added, the solution was adjusted to ph 7 with NaOH and extracted with methylene chloride. Drying and concentrating left a residue of ca. 1 g which was purified by chromatography (silica gel, methylene chloride methanol 8:2).
Yield: 0,38 g (43 % of th.) Fp. 133° (decomposition) C^H.aFaNnS (MG 511)

Examples of pharmacological administration forms
A) Tablets
Tablets of the following composition were molded, in a customary manner, on a compressed-tablet machine:
40 mg of the substance of Example 1
120 mg of corn starch
13.5mg of gelatin
45 mg of lactose
2.25mg of Aerosil® (chemically pure silicic acid
which is finely divided to the submicroscopic level)
6.75mg of potato starch (as a 6 % strength paste)
B) Coated tablets
20 mg of the substance of Example 4
60 mg of core mass
70 mg of saccharifying mass
The core mass consists of 9 parts of corn starch, 3 parts of lactose and 1 part of vinylpyrrolidone/vinyl acetate 60:40 mixed polymer. The saccharifying mass consists of
5 parts of cane sugar, 2 parts of corn starch, 2 parts of calcium carbonate and 1 part of talc. The coated tablets which have been prepared in this way are then provided with a gastric juice-resistant coating.
Biological investigations - receptor-binding studies
1) D3-binding test
Cloned human D3 receptor-expressing CCL 1,3 mouse fibro¬blasts, which can be obtained from Res. Biochemicals Internat., One Strathmore Rd., Natick, MA 01760-2418 USA, were used for the binding studies.

Cell preparation
The D3-expessing cells were multiplied in RPMI-1640 containing 10 % fetal calf serum (GIBCO No. 041-32400 N); 100 U/ml penicillin and 0.2 % streptomycin (GIBCO BRL, Gaithersburg, MD, USA). After 48 h, the cells were washed with PBS and incubated for 5 min with 0.05 % trypsin-containing PBS. After that, the mixture was neutralized with medium and the cells were collected by centrifuging at 300 g. In order to lyse the cells, the pellet was briefly washed with lysis buffer (5mM tris-HCl, pH 7.4, containing 10 % glycerol) and then incubated, at 4°C for 30 min, at a concentration of 107 cells/ml of lysis buffer. The cells were centrifuged at 200 g for 10 min and the pellet was stored in liquid nitrogen.
Binding tests
For the D3 receptor-binding test, the membranes were suspended in incubation buffer (50 mM tris-HCl, pH 7.4, containing 120 mM NaCl, 5 mM KC1, 2 mM CaCl2, 2 mM MgCl2, 10(iM quinolinol, 0.1 % of ascorbic acid and 0.1 % BSA) at a concentration of approx. 106 cells/250 fil of test mixture and incubated at 30°C with 0.1 nM 125iodosulpride in the presence and absence of test substance. The nonspecific binding was determined using 10-6M spiperone.
After 60 min, the free and the bound radio ligand were separated by filtration through GF/B glass fiber filters (Whatman, England) on a Skatron cell collector (Skatron, Lier, Norway) and the filters were washed with ice-cold tris-HCl buffer, pH 7.4. The radioactivity which had collected on the filters was quantified using a Packard 2200 CA liquid scintillation counter.
The Ki values were determined by means of nonlinear regression analysis using the LIGAND program.
2) D2-binding test
Cell culture
HEK-293 cells, possessing stably expressed human dopamine D2A receptors, were cultured in RPMI 1640 containing Glutamax I™ and 25 mM HEPES containing 10% fetal calf serum albumin. All

E CLAIM: 1. A triazole compound of the formula I

where
Ar^ Is phenyl, naphthyl or a 5- or B-membered heterocyclic aromatic ring having from 1 to 4 heter-oatoms which are selected, Independently of one another, from 0, S and N, where Ar1 may have 1, 2, 3 or 4 substituents which are selected, independently of each other, from C1-C6-all A is straight-chain or branched C4-C10-alkylene or straight-chain or branched C3-C10-altcylene
which comprises at least one Z group which is selected from O, S, NR2, C0NR2, COO, CO, or a double or triple bond,
B Is a radical of the formula:

or if Ar1 is the 5- or 6-membered heterocyclic aromatic ring which can be substituted as above, B is also a radical of the formulae

Ar2 is phenyl, pyridyl, pyrimidinyl or triazinyl, where At^ may have from 1 to 4 substituents which are selected, Independently of each other, from OR^, C1-C6-alkyl, Cj-C6-alkenyl, C2-C6-alkynyi, C^-C6-alkoxy-C1-6-alkyl, halogen-C,-C6-a!kyl, halogen-C1-6-alkoxy, halogen, CN, NOj,
SO2R2, NR2R2, SOgNR^R^, a 5- or 6-membered carbocycHc, aromatic or non-aronnatic ring and a 5- or 6-membered, heterocyclic aromatic or non-aromatic ring having 1 or 2 heteroatoms which are selected from O, S and N, where the carbocyclic or heterocyclic ring may be substi¬tuted by C1-6-allcyi, phenyl, phenoxy, halogen, OC1-6-alkyl, OH, NOj or CF3 and/or fused to a phenyl ring and where Ar^ may be. fused to a carbocyclic, aromatic or non-aromatic ring and a 5- or 6-membered, heterocyclic aromatic or non-aromatic ring having 1 or 2 heteroatoms which are selected from O, S and N,
R1 is H, Cs-C6-cycioalicyi or C^-C6-ailcyi which may be substituted by OH, OC1-6-allcyl or phenyl,
the radicals R2, which can be identical or different, are H or C^-C6-aii^yl, which may be substituted by OH, OC,-C6-alkyl or phenyl;
and their salts with physiologically tolerated acids, with the exception of the compounds

2. The compound of the formula I as claimed in claim 1, where
Ar^ is phenyl, naphthyl or a 5- or 6-memberecl heteroq/cllc aromatic ring having from 1 to 3 heter-oatoms which are selected from 0, S and N, where Ar1 may have 1,2,3 or 4 substituents which are selected, independently of each other, from C1-6-alkyI, which may be substituted by OH, OC1-6-alkyI, halogen orphenyl, C1-6-alkoxy, C1-6-alkenyl, C2-6-alkynyl, C3-C6-cycloalkyl, halogen, CN, C00R2, NR2R2, NOg, SOgR^. SOgNRSR^ orphenyl, which may be substituted by Ci-C6-all A Is straight-chain or branched C4-C10-alkylene or straight-chain or branched C3-C10-alkylene which comprises at least one group which is selected from O, S, NR2, CONR2, COO, CO, or a double or triple bond,
Q is a radical of the famnula:

Ar2 is phenyl, pyridyl, pyrimidinyl or triazinyl, where Ar2 may have from 1 to 4 substituents which
are selected, independently of each other, from 0R2, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy-C1-C6-alkyl, halogen-C1-6-alkyl, halogen-C1-C6-alkoxy, halogen, CN, NO2, SO2R2, NR2R2, SO2NR2R2, a 5- or 6-membered carbocyclte, aromatic or non-aromatic ring and a 5-or 6-membered, heterocyclic aromatfc or non-aromatic ring having 1 or 2 heteroatoms which are selected from O, S and N, where the carbocydic or heterocyclic ring may be substituted by C1-C6-a)kyl, phenyl, phenoxy, halogen, OC1-C6-alkyI, OH, NO2 or CF3 and where Ar2 may be fused to a carbocydic or heterocyclic ring of the above-defined nature.
R^ is H, C3-Ce-cycloalkyl or C1-6-alkyl which may be substituted by OH, OC1-6-alkyl or phenyl;
the radicals R2, " which can be identical or different, are H or C1-6-alkyl, which may be substituted by OH, OC1-6-alkyl or phenyl;
and their salts with physioiogteatly tolerated acids.
3. The compound of the fonnuia I as claimed In claim 1 or 2, where A Is C4-C10-alkylene or C3-C10-alkylene which may comprise at least one Z group which is selected from O, S and a double or triple bond.
\. The compound of the fomnula I as claimed in one of the preceding claims, where Ar^ is phpnyl, naphthyl, pyrrolyl, thienyl, furanyl, thiazolyl, imidazolyl, oxazolyl, oxadlazolyl, tetrazolyl, isoxazolyl, pyridinyi, pyrazinyl, pyrimidinyl, benzthiophenyl, indolyl or benzofuranyl, where Ar^ can, as indicated In claim 1, be substituted or fused.
. The compound of the formula I as claimed in claim 4, where Ar^ is phenyl, thienyl, furanyl, tetrazolyl, pyrrolyl or pyrazinyl and can, as indicated in claim 1, be substituted.
). The compound of the formula I as claimed In one of the preceding claims, where Ar^ is unsubstituted or has 1, 2, 3 or 4 substituents whteh are selected. Independently of each other, from CN, C1-6-aikyI, OH, OC1-6-alkyl, phenyl and halogen.

7. The compound of the formula I as claimed In one of the preceding claims, where R1 is H, C1-C6-allcyl or C3-C6-
cycloalkyl.
8. The compound of the formula I as claimed In one of the preceding claims, where Ar1 is phenyl, pyridinyl or pyrimidinyl
which may have one or two substituents which are selected, independently of each other, from C1-C6-alkyl, C2-C6-alkynyl, halogen, CN, haloall 9. The compound of a formula I as claimed in claim 8, wherein the substituent(s) is/are selected, independently of each
other, from C1-C6-alkyI, phenyl, NO2, and halogenoalltyl, in particular CF3, CHF2 and CF2CI.
10. Thecompound of the formula I as claimed In claim 1, where
Ar1 is phenyl which may be substituted by C1-C6-alkyl, OC1-C8-alkyl, CN, phenyl or halogen;
A has the meanings given in claim 2; B is

and
Ar2 is pyrimidinyl which may be substituted by C1-6-alkyl, halogen-C1-6-alkyl, halogen-C1-6-aikoxy, pyrrolyl or indolyl.
The compound of the formula I as claimed in claim 10, where
Ar1 is phenyl which may be substituted by C1-C6-alkyl, OC.,-Ce-alkyl or halogen, and
A is -8(CH2)3.10- or -(CH2)4-10-.
The compound of the fonnula I as claimed in one of claims 1 to 9, where Ar"" is a 5- or 6-membered heterocyclic aromatic ring having from 1 to 4 heteroatoms which are selected, Independently of each other, from 0. S and N, where the ring can, as indicated in claim 1, be substituted or fused, B is

and A and Ai^ have the meanings given in claim 1.
^13. A pharmaceutical composition which comprises at least one compound as claimed in one of claims 1 to 12, with or without physiologically acceptable carrier substance and/or auxiliary substances.
14. A compound of formula VIII

where Ar1 and R1 have the meanings given In one of the claims 1, 2, 4 to 7. 10 and 11, with the exception of :ompounds in which R1 is H and Ar1 is phenyl, p-tolyl, 2-, 3-, 4-pyridyl, p-chlorophenyl or p-nltrophenyl.

Documents:

1509-mas-98 assignment.pdf

1509-mas-98 claims-duplicate.pdf

1509-mas-98 claims.pdf

1509-mas-98 correspondence-others.pdf

1509-mas-98 correspondence-po.pdf

1509-mas-98 description (complete)-duplicate.pdf

1509-mas-98 description (complete).pdf

1509-mas-98 form-19.pdf

1509-mas-98 form-2.pdf

1509-mas-98 form-26.pdf

1509-mas-98 form-4.pdf

1509-mas-98 form-6.pdf

1509-mas-98 others.pdf

1509-mas-98 petition.pdf

« Previous Patent

Next Patent »

Patent Number

217725

Indian Patent Application Number

1509/MAS/1998

PG Journal Number

21/2008

Publication Date

23-May-2008

Grant Date

28-Mar-2008

Date of Filing

06-Jul-1998

Name of Patentee

ABBOTTGMBH & CO KG

Applicant Address

MAX-PLANEK-RING, 2,65205 WIESBADE,

Inventors:

#	Inventor's Name	Inventor's Address
1	DOROTHEA STARCK	MAX-PLANEK-RING,2,65205 WIESBADE,

PCT International Classification Number

C 07 D 240/12

PCT International Application Number

N/A

PCT International Filing date

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1	197 28 996.7	1997-07-07	Germany